News - Ampyra


Current filters:


Popular Filters

US FDA points to seizure risk with Acorda's MS drug Ampyra


The US Food and Drug Administration has issued a warning about the risk of seizures in patients with…

Acorda TherapeuticsAmpyraNeurologicalNorth AmericaPharmaceuticalRegulation

European Commission gives conditional OK for Biogen Idec’s MS drug Fampyra


The European subsidiary of US biotech firm Biogen Idec (Nasdaq: BIIB) has received conditional approval…

Acorda TherapeuticsAmpyraBiogen IdecEuropeFampyraNeurologicalPharmaceuticalRegulation

Strong launch for Novartis’ Gilenya despite its time-consuming initiation process; study


Swiss drug major Novartis' (NOVN: VX) recently-approved oral multiple sclerosis drug Gilenya (fingolimod)…

Acorda TherapeuticsAmpyraGilenyaMarkets & MarketingNeurologicalNovartisPharmaceutical

Australia’s TGA approves Biogen’s Fampyra to improve MS patients walking ability


The Australian Therapeutic Goods Administration (TGA) has granted approval for USA-based Biogen Idec’s…

AmpyraAsia-PacificBiogen IdecFampyraNeurologicalPharmaceuticalRegulation

Back to top